Private Equity Tempus Buys Highline SciencesThe acquisition will allow Tempus to vertically integrate more clinical trial services into its CRO partnerships. February 8, 2022
Healthcare Agilent Backs Resolution BioscienceAgilent expects the acquisition to expand its capabilities in NGS-based cancer diagnostics. March 2, 2021